HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases
Journal of Internal Medicine · 2023
DOI: 10.1111/joim.13616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, 2023. Verfasst von Marthe Kirkesaether Brun und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Antibody Formation, Celiac Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Akershus Universitetssykehus.
Abstract (Originalsprache)
Background
Immunogenicity to tumour necrosis factor inhibitors is a significant clinical problem leading to treatment failure and adverse events. The study aimed to assess human leukocyte antigen (HLA) associations with anti‐drug antibody (ADAb) formation to infliximab.
Methods
Immune‐mediated inflammatory disease patients on infliximab therapy ( n = 612) were included. Neutralising ADAb were assessed with a drug‐sensitive assay. Next generation sequencing‐based HLA typing was performed.
Results
Overall, 147 (24%) patients developed ADAb. Conditional analyses indicated HLA‐DQB1 ( p = 1.4 × 10 −6 ) as a primary risk locus. Highest risk of ADAb was seen when carrying at least one of the HLA‐DQ2 haplotypes; DQB1*02:01–DQA1*05:01 or DQB1*02:02–DQA1*02:01 (OR 3.18, 95% CI 2.15–4.69 and p = 5.9 × 10 −9 ). Results were consistent across diseases and when adjusting for concomitant immunomodulator. Computational predictions indicated that these HLA‐DQ2 haplotypes bind to peptide motifs from infliximab light chain.
Conclusion
A genome‐wide significant association between two HLA‐DQ2 haplotypes and the risk of ADAb formation to infliximab was identified, suggesting that HLA‐DQ2 testing may facilitate personalised treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
- Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.
- Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.
- Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Marthe Kirkesaether Brun, Kristin Hammersbøen Bjørlykke, Marte K Viken, Grethe-Elisabeth Stenvik, Rolf A Klaasen, Johanna E Gehin, Espen A Haavardsholm, Guro Løvik Goll, Benedicte A Lie, Kristin Kaasen Jørgensen, Silje Watterdal Syversen
Förderung
- Akershus Universitetssykehus
Zitieren
APA
Brun, M. K., Bjørlykke, K. H., Viken, M. K., Stenvik, G. E., Klaasen, R. A., Gehin, J. E., Warren, D. J., Sexton, J., Sandanger, Ø., Kvien, T. K., Mørk, C., Haavardsholm, E. A., Jahnsen, J., Goll, G. L., Lie, B. A., Bolstad, N., Jørgensen, K. K., & Syversen, S. W. (2023). HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases. Journal of Internal Medicine. https://doi.org/10.1111/joim.13616
Vancouver
Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, et al. HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases. Journal of Internal Medicine. 2023. doi:10.1111/joim.13616
BibTeX
@article{Brun2023,
author = {Brun, Marthe Kirkesaether and Bjørlykke, Kristin Hammersbøen and Viken, Marte K and Stenvik, Grethe-Elisabeth and Klaasen, Rolf A and Gehin, Johanna E and Warren, David John and Sexton, Joseph and Sandanger, Øystein and Kvien, Tore K and Mørk, Cato and Haavardsholm, Espen A and Jahnsen, Jørgen and Goll, Guro Løvik and Lie, Benedicte A and Bolstad, Nils and Jørgensen, Kristin Kaasen and Syversen, Silje Watterdal},
title = {HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases},
journal = {Journal of Internal Medicine},
year = {2023},
doi = {10.1111/joim.13616}
}
EUVIMED